Literature DB >> 6112537

Malignant melanoma in renal-transplant recipients.

M H Greene, T I Young, W H Clark.   

Abstract

14 patients who developed cutaneous malignant melanoma (CMM) after renal transplantation were studied. Histological review of the primary melanomas revealed that all 10 evaluable patients had a precursor naevus from which the CMM arose, 7 of which were dysplastic, and that 13 of the 14 patients had an abnormal host response to the tumour, characterised by absence of the usual lymphocyte/ macrophage infiltrate. These observations suggest that CMM in renal-transplant recipients evolves from precursor naevi in immunosuppressed patients who are unable to mount an appropriate cellular immune response to neoplastic cells. The clinical detection of dysplastic naevi offers an opportunity to identify in advance those immunosuppressed patients who are prone to melanoma and to modify their medical management accordingly.

Entities:  

Mesh:

Year:  1981        PMID: 6112537     DOI: 10.1016/s0140-6736(81)92359-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

1.  Increased risk of second primary cancers after a diagnosis of melanoma.

Authors:  Porcia T Bradford; D Michal Freedman; Alisa M Goldstein; Margaret A Tucker
Journal:  Arch Dermatol       Date:  2010-03

Review 2.  Metastatic melanoma and immunotherapy.

Authors:  Benjamin Herzberg; David E Fisher
Journal:  Clin Immunol       Date:  2016-07-16       Impact factor: 3.969

3.  Dermatology-important advances in clinical medicine: dysplastic nevus syndrome.

Authors:  E A Abel
Journal:  West J Med       Date:  1983-06

Review 4.  Cancer after transplantation.

Authors:  A G Sheil
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

5.  Cancer in organ transplant recipients: part of an induced immune deficiency syndrome.

Authors:  A G Sheil
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-03

6.  Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota.

Authors:  Siddhant Yadav; Siddharth Singh; W Scott Harmsen; Jithinraj Edakkanambeth Varayil; William J Tremaine; Edward V Loftus
Journal:  Mayo Clin Proc       Date:  2015-05-09       Impact factor: 7.616

7.  Excess benign melanocytic naevi after chemotherapy for malignancy in childhood.

Authors:  B R Hughes; W J Cunliffe; C C Bailey
Journal:  BMJ       Date:  1989-07-08

Review 8.  Melanoma in immunosuppressed patients.

Authors:  Agnieszka W Kubica; Jerry D Brewer
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

9.  Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review.

Authors:  P Dillon; N Thomas; N Sharpless; F Collichio
Journal:  Med Oncol       Date:  2009-11-05       Impact factor: 3.064

10.  Melanoma in patients with GATA2 deficiency.

Authors:  Jannett Nguyen; Tiffany Alexander; Hong Jiang; Natasha Hill; Zied Abdullaev; Svetlana D Pack; Amy P Hsu; Steven M Holland; Dennis D Hickstein; Eric A Engels; Isaac Brownell
Journal:  Pigment Cell Melanoma Res       Date:  2017-12-10       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.